Hope Bancorp, Inc.

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company's lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31 st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan.

LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope, has received all regulatory approvals required to complete the previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). Regulatory approvals have been received from the Federal Deposit Insurance Corporation and the California.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--